Cargando…

Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression

Vγ9Vδ2 T cells are non-conventional T cells with a natural inclination to recognize and kill cancer cells. Malignant B cells, including myeloma cells, are privileged targets of Vγ9Vδ2 T cells in vitro. However, this inclination is often lost in vivo due to multiple mechanisms mediated by tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castella, Barbara, Foglietta, Myriam, Riganti, Chiara, Massaia, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6036291/ https://www.ncbi.nlm.nih.gov/pubmed/30013559 http://dx.doi.org/10.3389/fimmu.2018.01492

Ejemplares similares

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma
por: Castella, Barbara, et al.
Publicado: (2018)

Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
por: Castella, Barbara, et al.
Publicado: (2015)

The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells
por: Castella, Barbara, et al.
Publicado: (2017)

Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status
por: Giannotta, Claudia, et al.
Publicado: (2022)

Vγ9Vδ2 T-cell immunotherapy in blood cancers: ready for prime time?
por: Giannotta, Claudia, et al.
Publicado: (2023)

ABCA1, apoA-I, and BTN3A1: A Legitimate Ménage à Trois in Dendritic Cells
por: Riganti, Chiara, et al.
Publicado: (2018)

The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells
por: Giannotta, Claudia, et al.
Publicado: (2023)

Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells
por: Rigoni, Micol, et al.
Publicado: (2015)

Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells: Killing two birds with one stone
por: Riganti, Chiara, et al.
Publicado: (2013)

Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells
por: Gu, Siyi, et al.
Publicado: (2015)

Role of Vγ9vδ2 T lymphocytes in infectious diseases
por: Gay, Laetitia, et al.
Publicado: (2022)

Phenotype and functional changes of Vγ9/Vδ2 T lymphocytes in Behçet's disease and the effect of infliximab on Vγ9/Vδ2 T cell expansion, activation and cytotoxicity
por: Accardo-Palumbo, Antonina, et al.
Publicado: (2010)

The human Vδ2(+) T-cell compartment comprises distinct innate-like Vγ9(+) and adaptive Vγ9(-) subsets
por: Davey, Martin S., et al.
Publicado: (2018)

Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
por: Hoeres, Timm, et al.
Publicado: (2018)

Development and Selection of the Human Vγ9Vδ2(+) T-Cell Repertoire
por: Willcox, Carrie R., et al.
Publicado: (2018)

The PPARα pathway in Vγ9Vδ2 T cell anergy
por: Poupot, Mary, et al.
Publicado: (2014)

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy
por: Ridgley, Laura A., et al.
Publicado: (2023)

Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth
por: Zhang, Xi, et al.
Publicado: (2022)

Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme
por: Lee, Mijeong, et al.
Publicado: (2019)

CD137 Costimulation Enhances the Antitumor Activity of Vγ9Vδ2-T Cells in IL-10-Mediated Immunosuppressive Tumor Microenvironment
por: Pei, Yujun, et al.
Publicado: (2022)

Role of Vγ9Vδ2+ γδ T cells in juvenile idiopathic arthritis
por: Gerstein, M, et al.
Publicado: (2008)

BTLA, a key regulator of Vγ9Vδ2 T-cell proliferation
por: Gertner-Dardenne, Julie, et al.
Publicado: (2013)

An Update on the Molecular Basis of Phosphoantigen Recognition by Vγ9Vδ2 T Cells
por: Herrmann, Thomas, et al.
Publicado: (2020)

HIV Infection of Monocytes-Derived Dendritic Cells Inhibits Vγ9Vδ2 T Cells Functions
por: Sacchi, Alessandra, et al.
Publicado: (2014)

Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells
por: Riganti, Chiara, et al.
Publicado: (2013)

Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth
por: Mao, Tsui Lien, et al.
Publicado: (2019)

Vγ9Vδ2 T cell-mediated non-cytolytic antiviral mechanisms and their potential for cell-based therapy
por: Poccia, Fabrizio, et al.
Publicado: (2005)

Human Vγ9Vδ2 T Lymphocytes in the Immune Response to P. falciparum Infection
por: Howard, Jennifer, et al.
Publicado: (2018)

Mistletoe-Extract Drugs Stimulate Anti-Cancer Vγ9Vδ2 T Cells
por: Ma, Ling, et al.
Publicado: (2020)

Functional Phenotypes of Human Vγ9Vδ2 T Cells in Lymphoid Stress Surveillance
por: Nussbaumer, Oliver, et al.
Publicado: (2020)

Effector Vγ9Vδ2 T cell response to congenital Toxoplasma gondii infection
por: Ma, Ling, et al.
Publicado: (2021)

Generation and application of TGFβ-educated human Vγ9Vδ2 T cells
por: Parente-Pereira, Ana C., et al.
Publicado: (2022)

Interferon-α Improves Phosphoantigen-Induced Vγ9Vδ2 T-Cells Interferon-γ Production during Chronic HCV Infection
por: Cimini, Eleonora, et al.
Publicado: (2012)

Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome
por: Toia, Francesca, et al.
Publicado: (2016)

Specific tumor targeting and activation of Vγ9Vδ2 T cells by bi-specific nanobodies
por: Stam, Anita, et al.
Publicado: (2014)

Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection
por: Soriano-Sarabia, Natalia, et al.
Publicado: (2015)

Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells
por: Domae, Eisuke, et al.
Publicado: (2017)

Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins
por: Laplagne, Chloé, et al.
Publicado: (2021)

TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer
por: Beatson, Richard E., et al.
Publicado: (2021)

Generation of effector Vγ9Vδ2 T cells and evaluation of their response to phosphoantigen-loaded cells
por: Hsiao, Chia-Hung Christine, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6vke4vkq49u5qmnigogvdo9kfj